Patents by Inventor Volker Schellenberger

Volker Schellenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 10961287
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 30, 2021
    Assignee: Amunix Pharmaceuticals, Inc
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • XTEN conjugate compositions and methods of making same
    Patent number: 10953073
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 23, 2021
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME
    Publication number: 20210054077
    Abstract: This disclosure relates to compositions having an antibody binding fragment that specifically binds to CD3 or an epitope thereof. Some embodiments include compositions and antibody binding fragments with increased stability. Bispecific fusion proteins including such antibody-binding fragments are also disclosed.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 25, 2021
    Inventors: Volker Schellenberger, Philipp Kuhn, André Frenzel, Darragh MacCann, James McClory
  • Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same
    Patent number: 10870874
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 22, 2020
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. C. Stemmer, Nathan C. Geething
  • GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20200392195
    Abstract: The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acides encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2 related conditions.
    Type: Application
    Filed: January 30, 2020
    Publication date: December 17, 2020
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Benjamin Spink
  • RELEASE SEGMENTS AND BINDING COMPOSITIONS COMPRISING SAME
    Publication number: 20200385469
    Abstract: The present invention relates to activatable recombinant polypeptide compositions comprising a cleavage release segment. In some instances, the activatable recombinant polypeptide compositions include an XTEN linked to binding moieties by cleavable release segments that, when cleaved, the binding moieties are capable of binding together effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable activatable recombinant compositions.
    Type: Application
    Filed: December 20, 2018
    Publication date: December 10, 2020
    Inventors: Fan YANG, Volker SCHELLENBERGER, Vladimir PODUST, Bee-Cheng SIM, Desiree THAYER, John BEABER
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20200087379
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: July 25, 2019
    Publication date: March 19, 2020
    Inventors: Volker Schellenberger, Pei-Yun Chang, Fatbardha Varfaj, Sheng Ding, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei
  • Factor VIII-XTEN fusions and uses thereof
    Patent number: 10548953
    Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: February 4, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Tongyao Liu, Pei-Yun Chang, John Kulman, Volker Schellenberger, Haiyan Jiang, Robert T. Peters, Ekta Seth Chhabra
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20190315835
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 17, 2019
    Inventors: Volker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
  • Factor VIII compositions and methods of making and using same
    Patent number: 10421798
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: September 24, 2019
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Volker Schellenberger, Pei-Yun Chang, Fatbardha Varfaj, Sheng Ding, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Volker Schellenberger, Nathan Geething, John Kulman, Tongyao Liu, Garabet G. Toby, Haiyan Jiang, Robert Peters, Deping Wang, Baisong Mei
  • CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20190153115
    Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
    Type: Application
    Filed: August 26, 2016
    Publication date: May 23, 2019
    Inventors: Volker SCHELLENBERGER, Fan YANG, Desiree THAYER, Bee-Cheng SIM, Chia-Wei WANG
  • XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME
    Publication number: 20190083577
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 21, 2019
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant MCLAUGHLIN, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • Multi-through hole testing plate for high throughput screening
    Patent number: 10195579
    Abstract: A method for holding samples for analysis and an apparatus thereof includes a testing plate with a pair of opposing surfaces and a plurality of holes. Each of the holes extends from one of the opposing surfaces to the other one of the opposing surfaces. The holes are arranged in groups, where each group has at least two rows and two columns of holes. The groups are arranged in sets, where each set has at least two rows and two columns of groups. To analyze samples, at least one of the opposing surfaces of the testing plate is immersed in a solution to be analyzed. A portion of the solution enters openings for each of the holes in the immersed opposing surface. Once the holes are filled with solution, the testing plate is removed and is held above a supporting surface. Surface tension holds the solution in each of the holes. The solution in one or more of the holes is then analyzed and the solution in one of these holes is identified for further study.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 5, 2019
    Assignee: Life Technologies Corporation
    Inventors: Volker Schellenberger, Amy Liu
  • XTEN conjugate compositions and methods of making same
    Patent number: 10172953
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: January 8, 2019
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME
    Publication number: 20180346952
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Application
    Filed: April 17, 2018
    Publication date: December 6, 2018
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P.C Stemmer, Nathan C. Geething
  • EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME
    Publication number: 20180244736
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: February 2, 2018
    Publication date: August 30, 2018
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Blood glucose lowering compound
    Patent number: 10035839
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 31, 2018
    Assignees: Eli Lilly and Company, Amunix Operating Inc.
    Inventors: David Bruce Baldwin, John Michael Beals, Andrew Ihor Korytko, Bryant Rhodius McLaughlin, Volker Schellenberger
  • Glucose-regulating polypeptides and methods of making and using same
    Patent number: 10000543
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 19, 2018
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • GROWTH HORMONE POLYPEPTIDES AND METHODS OF MAKING AND USING SAME
    Publication number: 20180161443
    Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
    Type: Application
    Filed: November 8, 2017
    Publication date: June 14, 2018
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland, Benjamin Spink
  • Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same
    Patent number: 9976166
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 22, 2018
    Assignee: AMUNIX OPERATING INC.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. C. Stemmer, Nathan C. Geething